Burning Rock Biotech Limited (BNR) Earnings Call Analysis

NASDAQ · Healthcare · Diagnostics & Research

18/25

Growth 4 Margin 2 Expansion 4 Platform 5 Financial 3

latest quarter score

Earnings Reports

Burning Rock (BNR) Q1 2024: In-Hospital Revenue Mix Surpasses 50%, Marking Strategic Inflection
May 29, 2024
Burning Rock (BNR) Q4 2023: Pharma Segment Grows 59% as Cost Cuts Drive Path to Profitability
March 29, 2024
18
Burning Rock (BNR) Q3 2023: In-Hospital Revenue Rises 10% as Central Lab Contracts 41%, Accelerating Strategic Channel Shift
November 30, 2023
Burning Rock (BNR) Q2 2023: In-Hospital Test Volumes Surge 72% as Profitability Milestone Reached
August 31, 2023
Burning Rock (BNR) Q1 2023: Biopharma Contract Value Up 27% as Margin Efficiency Drives Breakeven Path
May 30, 2023
Burning Rock (BNR) Q4 2022: Pharma Revenue Surges 200% as MRD, Early Detection Drive Multi-Year Growth Path
March 28, 2023

Browse all companies